Pharmacyte Biotech earnings were -$20.6M for the trailing 12 months ending Jul 31, 2026, with N/A growth year over year. The latest PMCB earnings report on Jul 31, 2026 announced Q3 2026 earnings of -$5.8M, up 18.7% from last quarter. For the last reported fiscal year 2026 ending Apr 30, 2026, PMCB reported annual earnings of -$23.2M, with -199.3% growth.
What were Pharmacyte Biotech's earnings last quarter?
Pharmacyte Biotech (NASDAQ: PMCB) reported Q2 2026 earnings per share (EPS) of -$0.54, up 56.1% year over year. Total PMCB earnings for the quarter were -$5.79 million. In the same quarter last year, Pharmacyte Biotech's earnings per share (EPS) was -$1.23.
As of the last Pharmacyte Biotech earnings report, Pharmacyte Biotech is currently losing money. Pharmacyte Biotech's net profit (also called net income) for the twelve months ending Jul 31, 2026 was -$16.15 million, a 1,334.67% increase year over year.
What was PMCB's earnings growth in the past year?
As of Pharmacyte Biotech's earnings date in Q3 2026, Pharmacyte Biotech's earnings has grown year over year. PMCB earnings in the past year totalled -$20.63 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.